The Competition Commission of India (CCI) has approved the Proposed Combination involving acquisition of 100% of the equity shares of Tianish Laboratories Private Limited by the Matrix Pharma Private Limited.
Banking & Finance
The Competition Commission of India (CCI) has approved the Proposed Combination involving acquisition of 100% of the equity shares of Tianish Laboratories Private Limited by the Matrix Pharma Private Limited. Kotak Strategic Situations India Fund II (Investor 1) is an alternative investment fund registered with the Securities and Exchange Board of India (SEBI) under the SEBI (Alternative Investment Funds) Regulations, 2012. Kotak Alternate Asset Managers Limited (Investor 2) acts as an investment manager, engaged in the business of managing and advising funds across the following asset classes namely: (a) Special Situations; (b) Real Estate; (c) Infrastructure; (d) Private Equity; and (e) Private Credit.
Matrix Pharma Private Limited (Acquirer) does not presently carry out any business activity either in India or outside India.
Competition Commission of India (CCI)
Commission executives- Ravneet Kaur IAS, (Chairperson); Jyoti Jindgar Bhanot, (Secretary)
____________________________
